SecSonar.com

Royalty Pharma plc (RPRX)

Royalty Pharma plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Royalty Pharma plc (RPRX) is a Biotechnology company based in US with a market capitalization of $23.6B. Revenue grew 5.1% year-over-year and the company generated $2.5B in free cash flow. This page tracks RPRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 75 employees · IPO Jun 16, 2020

Valuation

Valuation & price

$52.85 · as of May 17, 2026 · -7.4% vs 52w high

38.4

P/E ratio

Latest-FY diluted EPS

3.64

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$56.94$45.99$35.04Jul 25Dec 25Jul 26Jul 7, 25$35.59Jul 9, 25$35.87Jul 11, 25$35.84Jul 15, 25$36.51Jul 17, 25$35.47Jul 21, 25$35.65Jul 23, 25$36.01Jul 25, 25$36.67Jul 29, 25$37.27Jul 31, 25$36.80Aug 4, 25$37.88Aug 6, 25$37.12Aug 11, 25$36.19Aug 13, 25$36.46Aug 15, 25$36.35Aug 19, 25$36.00Aug 21, 25$36.31Aug 25, 25$35.99Aug 27, 25$36.06Aug 29, 25$35.98Sep 3, 25$36.66Sep 5, 25$36.07Sep 9, 25$36.50Sep 11, 25$36.70Sep 16, 25$35.42Sep 18, 25$35.73Sep 22, 25$35.86Sep 24, 25$35.77Sep 26, 25$35.04Sep 30, 25$35.28Oct 2, 25$36.49Oct 6, 25$36.13Oct 8, 25$36.02Oct 10, 25$36.01Oct 14, 25$36.00Oct 16, 25$36.34Oct 21, 25$37.48Oct 23, 25$36.85Oct 27, 25$37.26Oct 29, 25$36.67Oct 31, 25$37.54Nov 4, 25$37.84Nov 6, 25$40.78Nov 10, 25$38.54Nov 12, 25$39.59Nov 14, 25$39.16Nov 18, 25$39.46Nov 20, 25$38.39Nov 25, 25$39.54Nov 28, 25$40.02Dec 2, 25$39.53Dec 4, 25$39.15Dec 8, 25$38.67Dec 10, 25$38.26Dec 12, 25$38.39Dec 16, 25$38.38Dec 18, 25$38.43Dec 22, 25$38.86Dec 24, 25$39.25Dec 29, 25$39.08Jan 2, 26$38.86Jan 6, 26$40.65Jan 8, 26$40.26Jan 12, 26$40.26Jan 14, 26$40.21Jan 16, 26$39.55Jan 21, 26$39.72Jan 23, 26$40.40Jan 27, 26$40.74Jan 29, 26$40.86Feb 2, 26$42.36Feb 4, 26$43.68Feb 9, 26$44.05Feb 11, 26$44.25Feb 13, 26$45.19Feb 18, 26$45.34Feb 20, 26$45.12Feb 24, 26$45.40Feb 26, 26$45.36Mar 2, 26$47.47Mar 4, 26$47.43Mar 6, 26$45.41Mar 10, 26$45.97Mar 12, 26$45.87Mar 17, 26$46.11Mar 19, 26$45.53Mar 23, 26$45.61Mar 25, 26$47.03Mar 27, 26$46.35Mar 31, 26$47.97Apr 2, 26$48.57Apr 7, 26$46.87Apr 9, 26$48.30Apr 13, 26$48.43Apr 15, 26$48.70Apr 17, 26$50.00Apr 22, 26$49.72Apr 24, 26$49.38Apr 28, 26$49.54Apr 30, 26$50.09May 4, 26$50.20May 6, 26$50.72May 8, 26$50.79May 12, 26$51.70May 14, 26$53.40May 18, 26$52.07May 20, 26$53.06May 22, 26$54.50May 28, 26$54.48Jun 1, 26$55.18Jun 3, 26$54.97Jun 5, 26$55.87Jun 9, 26$55.63Jun 11, 26$55.29Jun 15, 26$54.27Jun 17, 26$53.70Jun 22, 26$53.57Jun 24, 26$54.28Jun 26, 26$56.23Jul 2, 26$56.94
$34.9052-week range$57.09
Loading valuation history…

Fundamentals

Key fundamentals

$23.6B

Market cap

5.1%

Revenue growth (YoY)

100.0%

Gross margin

$2.5B

Free cash flow (USD)

$8.3B

Net debt

-3.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.9BFY 2017$1.6BFY 2018$1.8BFY 2019$1.8BFY 2020$2.1BFY 2021$2.3BFY 2022$2.2BFY 2023$2.4BFY 2024$2.3BFY 2025$2.4B
$1.9B$2.4B

Free cash flow by year

2017 → 2025

FY 2017$1.4BFY 2018$1.6BFY 2019$1.7BFY 2020$2.0BFY 2021$2.0BFY 2022$2.1BFY 2023$3.0BFY 2024$2.8BFY 2025$2.5B
$1.4B$2.5B

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $7.3M · 10b5-1 PlanHite Christopher · EVP & Chairman, Partnering · $7.3MJul 2, 2026Filing
  • Insider sellInsider Sell $8.2M · 10b5-1 PlanHite Christopher · EVP & Chairman, Partnering · $8.2MJun 25, 2026Filing
  • Insider sellInsider Sell $502K · 10b5-1 PlanUrist Marshall · EVP, Research & Investments · $502.1KJun 25, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • Insider sellInsider Sell $3.5M · 10b5-1 PlanCoyne Terrance P. · EVP & CFO · $3.5MMay 28, 2026Filing
  • 8-K eventDebt RefinancingMay 28, 2026Filing
  • Insider sellInsider Sell $722K · 10b5-1 PlanUrist Marshall · EVP, Research & Investments · $721.8KMay 21, 2026Filing
  • Insider sellInsider Sell $161K · 10b5-1 PlanNorden Gregory · Director · $161.4KMay 15, 2026Filing
  • Insider sellInsider Sell $726K · 10b5-1 PlanUrist Marshall · EVP, Research & Investments · $726.1KMay 15, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing

Questions

Frequently asked questions

What is Royalty Pharma plc's market cap?

Royalty Pharma plc (RPRX) has a market capitalization of $23.6B.

What is RPRX's P/E ratio?

RPRX trades at a price-to-earnings ratio of 38.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is RPRX's price-to-book (P/B) ratio?

RPRX trades at 3.64 times book value per share.

Are insiders buying RPRX stock?

SEC Form 4 filings show no open-market insider buys at Royalty Pharma plc in the last 90 days (8 sells).

Same arena

Related companies in Biotechnology

UTHR

United Therapeutics Corporation

$23.4B

INSM

Insmed Incorporated

$23.3B

ROIV

Roivant Sciences Ltd.

$21.7B

INCY

Incyte Corporation

$19.5B

MRNA

Moderna, Inc.

$19.3B

GMAB

Genmab A/S

$16.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.